BB BIOTECH
BB BIOTECH
Open: -
Change: -
Volume: -
Low: -
High: -
High / Low range: -
Type: Stocks
Ticker: BB
ISIN: CH0038389992

DGAP-Adhoc: BB Biotech AG publishes its interim report

  • 78

DGAP-Ad-hoc: BB BIOTECH AG / Key word(s): Interim Report
BB Biotech AG publishes its interim report

18-Oct-2019 / 07:00 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Media release of October 18, 2019

Interim report of BB Biotech AG as at September 30, 2019

BB Biotech AG publishes its interim report

BB Biotech AG (ISIN CH0038389992) today published its interim report as at September 30, 2019, which covers the results of its business activities for the first nine months of 2019.

Based on the consolidated accounts of BB Biotech AG, net profit for the period ended September 30, 2019 amounted to CHF 172 mn (profit of CHF 172 mn in the same period 2018). In the third quarter a loss of CHF 382 mn (profit of CHF 242 mn in the corresponding period of the previous year) was incurred. For an investment company, the reported result reflects the performance of the stocks that it holds in its portfolio.

BB Biotech AG's interim report as at September 30, 2019 can be downloaded at www.bbbiotech.com.

For further information:

Investor Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, Tel. +41 44 267 67 00
Dr. Silvia Siegfried-Schanz, [email protected]
Maria-Grazia Iten-Alderuccio, [email protected]
Claude Mikkelsen, [email protected]

Media Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, Tel. +41 44 267 67 00
Tanja Chicherio, [email protected]

TE Communications AG, Bleichestrasse 11, 9000 St. Gallen, Switzerland, Tel. +41 79 423 22 28
Thomas Egger, [email protected]

www.bbbiotech.com

Company profile
BB Biotech AG invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector.
BB Biotech AG is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech AG's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.


18-Oct-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: BB BIOTECH AG
Schwertstrasse 6
8200 Schaffhausen
Switzerland
Phone: +41 52 624 08 45
E-mail: [email protected]
Internet: www.bbbiotech.ch
ISIN: CH0038389992
WKN: A0NFN3
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart; SIX
EQS News ID: 891769

 
End of Announcement DGAP News Service

891769  18-Oct-2019 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=891769&application_name=news&site_id=centralchart
EQS Group
EQS Group

EQS Group is a leading international technology provider for Digital Investor Relations, Corporate Communications and Compliance. More than 8,000 companies worldwide trust EQS’s products and services to securely, efficiently, and simultaneously fulfil complex national and international disclosure and compliance requirements, and to reach stakeholders globally.